Seon Ye Kim

980 total citations · 1 hit paper
12 papers, 798 citations indexed

About

Seon Ye Kim is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Seon Ye Kim has authored 12 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Seon Ye Kim's work include Lung Cancer Treatments and Mutations (5 papers), Cancer therapeutics and mechanisms (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Seon Ye Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer therapeutics and mechanisms (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Seon Ye Kim collaborates with scholars based in South Korea, China and United States. Seon Ye Kim's co-authors include Jae Cheol Lee, Jin Kyung Rho, Chang‐Min Choi, Yun Jung Choi, Ki Jung Sung, Young Hoon Sung, Woo Sung Kim, Dong Ha Kim, Miyong Yun and Soo Jeong Nam and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Seon Ye Kim

12 papers receiving 791 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer

2019 315 citations Dong Ha Kim, Yun Jung Choi et al. Experimental & Molecular Medicine profile →

Peers

Countries citing papers authored by Seon Ye Kim

Since Specialization

Citations

This map shows the geographic impact of Seon Ye Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seon Ye Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seon Ye Kim more than expected).

Fields of papers citing papers by Seon Ye Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seon Ye Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seon Ye Kim. The network helps show where Seon Ye Kim may publish in the future.

Co-authorship network of co-authors of Seon Ye Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Seon Ye Kim. A scholar is included among the top collaborators of Seon Ye Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seon Ye Kim. Seon Ye Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 2021 ·Scientific Reports ·(unknown), Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, (unknown), (unknown), Chang‐Min Choi, Young Hoon Sung, Jae Cheol Lee, Jin Kyung Rho	35
2	Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4 2020 ·Cancer Letters ·Dong Ha Kim, Sojung Park, (unknown), Yun Jung Choi, Seon Ye Kim, Ki Jung Sung, Young Hoon Sung, Chang‐Min Choi, Miyong Yun, Young‐Su Yi, (unknown), Sang‐Yeob Kim, Jae Cheol Lee, Jin Kyung Rho	84
3	Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer 2020 ·Targeted Oncology ·Yong‐Hee Cho, (unknown), (unknown), Yun Jung Choi, Seon Ye Kim, Ki Jung Sung, Jae Cheol Lee, Sang‐Yeob Kim, Jin Kyung Rho, Chang‐Min Choi	40
4	Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer breakdown → 2019 ·Experimental & Molecular Medicine ·Dong Ha Kim, (unknown), Yun Jung Choi, Seon Ye Kim, (unknown), Ki Jung Sung, Young Hoon Sung, Chan‐Gi Pack, Minkyo Jung, Buhm Han, Kun Hee Kim, Woo Sung Kim, Soo Jeong Nam, Chang‐Min Choi, Miyong Yun, Jae Cheol Lee, Jin Kyung Rho	315
5	Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation 2018 ·Cancer Research ·Ji Hye Kim, (unknown), Yun Jung Choi, Seon Ye Kim, (unknown), Ki Jung Sung, Woo Sung Kim, Chang‐Min Choi, Eun‐Ju Chang, Jae Soo Koh, Joon Seon Song, Shinkyo Yoon, Jae Cheol Lee, Jin Kyung Rho, Jaekyoung Son	60
6	Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer 2018 ·Targeted Oncology ·Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, (unknown), Ki Jung Sung, Young Hoon Sung, Woo Sung Kim, Sung-Eun Kim, (unknown), (unknown), Guangying Lu, Chang‐Min Choi, Jin Kyung Rho, Jae Cheol Lee	2
7	Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement 2017 ·Oncotarget ·Sehoon Choi, Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, (unknown), Ki Jung Sung, Woo Sung Kim, Chang‐Min Choi, Jin Kyung Rho, Jae Cheol Lee	13
8	Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer 2016 ·Oncotarget ·Ji Hyun Park, Yun Jung Choi, Seon Ye Kim, (unknown), Ki Jung Sung, Sojung Park, Woo Sung Kim, Joon Seon Song, Chang‐Min Choi, Young Hoon Sung, Jin Kyung Rho, Jae Cheol Lee	59
9	AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells. 2015 ·PubMed ·(unknown), Jin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Chang‐Min Choi, Young Jin Chun, Jae Cheol Lee	36
10	AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells 2015 ·PLoS ONE ·Yun Jung Choi, Seon Ye Kim, (unknown), In‐Jeoung Baek, Woo Sung Kim, Sehoon Choi, Jae Cheol Lee, Trever G. Bivona, Jin Kyung Rho, Chang‐Min Choi	22
11	MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation 2013 ·Cancer Research ·Jin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Tae Won Kim, Eun Kyung Choi, Seon-Joo Yoon, (unknown), Eunhye Park, (unknown), Chang‐Min Choi, Jae Cheol Lee	120
12	Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor 2013 ·Tuberculosis & respiratory diseases ·Youjin Chang, Seon Ye Kim, Yun Jung Choi, (unknown), Jin Kyung Rho, Woo Sung Kim, Jae Cheol Lee, Jin-Haeng Chung, Chang‐Min Choi	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact